2013 Oncology Intelligence

A Comprehensive Report for Decision Making

WHY I NEED A INTELLIGENCE REPORT ?

Yey! sounds good Report - covers all aspects of Cancer Drug Development Intelligence. To Explore who is developing what ?
Designed colorful magazine, for your reading pleasure. Exact Competition withlike my Drug on Launch. Can be read in flight between San Francisco should to Boston. inforamation be Top companies/developers stratergies. reliable and reading should not be Collaboration patterns to fill technology gap. INFOGRAPHICS BASED INTELLIGENCE REPORT. time Consuming. Emerging drug targets in cancer research. Year on year, which indications are advancing ? Role of emerging markets in sales/research competition? etc., etc. and so on.

but......

REPORT CONTAINS

Interactive 820+ pages, divided into 6 Sections, with Infographics and Tables

most updated information

2663
Indications In Trials

142
Cancer preclinical Pipeline Companies

462
Cancer Clinical Companies

210+
Cancer Targets

LatePreclinical Molecules

600+

1042
Molecules in Clinical Trials

Complete

2012
Cancer Drug Updates

Oncology Intelligence

A Comprenehsive Report for Decision Making 2013

REPORT IS DIVIDED IN 6 SECTIONS,

WITH INFOGRAPHICS AND CANCER COMPANIES PROFILES

ALL INFOGRAPHICS PAGES

462 COMPANIES

Total 6 Pages with 14 Figures and 1 Table

Worldwide Distribution of Oncology focused companies, with active clinical pipeline.

Helps in identifying the research incubating countries.

Division of Companies on the Basis of Market/Assets Valuation and Ownership, along with their country wise distribution.
Helps in identifying cancer research trends among Small, Mid & Large companies also as Public, Private & Subsidiaries, and nation wise preferences for the sector.

Division of Cancer Companies on the basis of employee numbers and Year of Incorporation.
Exploring cancer research funding needs and emergence of Cancer Drug Discovery Industry, going ahead.

Distribution of Cancer Companies within United States of America.

Helps in identifying the cancer research hubs and research supporting states.

Few Sample Pages of Section A

PAGES CONTAINS INFOGRAPHICS & TABLES

1042 MOLECULES & 210+ TARGETS

Total 55 Pages with 26 Figures & 25 Tables

Worldwide Distribution of cancer targeting molecules in clinical development.

Helps in identifying the emerging trends between Small molecules Vs. Biologics.

Molecule Developing Strategies - Top 10 Companies Vs. Remaining 452 Companies.

Identify How Big Pharma drug strategies are changing and what others are pursuing.

Cancer Drug Targets Established Vs. Emerging Targets.

210+ cancer drug targets with complete details and drugs under development for each target. Thus, helps in clearly identifying emerging targets.

Protein Kinases Inhibitors Development Strategies Top 10 Vs. Others.

Established Protein Kinases Vs emerging protein kinases- development profiles. Learn which companies are focusing more on PK and for which cancer indications.

Cancer Drugs in Development mAbs , Vaccines, mAbs-drug conjugates Gene Therapies & description of various others molecules.

Few Sample Pages of Section B

Page 2 & 3, shown above contains cuttings of various pages. For more details, kindly refer Table of Contents.

PAGES CONTAINS INFOGRAPHICS & TABLES

2663 DRUG INDICATIONS in 19 CANCER TYPES Total 81 Pages with 53 Figures & 91 Tables

Division of total drug Indications among top 19 cancer subtypes (like Lung, Breast, Melanoma, etc.)
Helps in identifying the emerging vs. current Cancer Indications.

Phase wise & Region wise, Distribution of Drug Indications.

Exploring who is developing what?

Cancer Indications Development Strategies - Top 10 companies Vs. others.

Identifying the emerging cancer subtypes of interest among Big Pharma and their choice towards development of small/biologics.

Complete Clinical Drug Development Profiles of 19 Cancer Subtypes.

Identifying the emerging Vs. underserved cancer subtype. First Report which equally focuses underserved cancer subtypes.

Orphan Drug Status molecules and their cancer indications (USFDA & EMEA). Oncology Clinical Pipeline Major Advances/Failures & New Entrants - 2012.

Few Sample Pages of Section C

For more details, kindly refer Table of Contents.

PAGES CONTAINS TABLES ONLY

Total 16 Pages with 9 Tables Complete coverage of oncology focused events (1000+ events).

Corporate Actions - 2012

US FDA Oncology Drug Approvals - 2012

Mergers & Acquisitions -2012

Partnering & Collaborations - 2012

Oncology molecule Assets Acquisition / Assets Termination - 2012 Company / Academic Partnerships - 2012 Venture Capital Financing - 2012 Key Management Appointments - 2012

Few Sample Pages of Section D

Pages 1,2 & 3, shown above contains cuttings of various pages. For more details, kindly refer Table of Contents.

PAGES CONTAINS 462 COMPANIES PROFILES

Total 526 Pages

Focused 462 individual cancer clinical companies profiles Mini Reports.

Companies having active clinical trials, with development & marketing rights of molecules in cancer treatment are only included. No company with dead assets (trials-status unknown/last updated prior 2010) are included.

Profile contains Companys key management, key oncology assets (both clinical & preclinical), key collaborators, Investors, Molecules profile, targets & development strategies etc.
Only Oncology focused events are documented, to avoid any ambiguous data.

Profiles are written as mini-report for an individual company.

All Inferences are derived in this report in earlier sections are based on these mini reports of companies , thus the report validates its data.

No Information is Duplicated.
The strongest point of Report, beside been precise is, no information is duplicated anywhere, that helps to avoid confusions/errors.

Oncology focused :- Key Highlights of Company, Key technology, Collaborations, partners, Approved pipeline, etc. Cancer Targeted Molecules in Clinical Development:Molecule name(s), Target, Clinical Phase, all possible Indications of development of the molecule, Last Updated on Clinical Trials with Trial Status as on Dec 2012 & Drug type (Small/Biologic/NBCM).

Management Profile: Contact Address, Founded Year, Ownership, Key Management People, Stock Ticker and Market Capitalization

Key Highlights of Drugs in Development :- Drugs Target Description, Mechanism of Action, Orphan Status, Preclinical Pipeline etc.

Company Profile Pages Merck Serono

PAGES CONTAINS 142 COMPANIES PROFILES

Total 95 Pages

Focused profiles of individual cancer companies, with active preclinical pipeline.

Companies with molecules in late preclinical development for cancer treatment.

Exclusive focus on Partnering and Emerging Proprietary Technology.

Description of First in class with molecules available for partnering.

Covers 300+ molecules in preclinical development.

Reports covers 600+ disclosed Preclinical Molecules in development by both clinical and preclinical companies.

Only Late Preclinical Pipeline companies are included.

No Exclusive Cancer Discovery Phase Companies are covered to avoid ambiguity.

Cancer Companies Profiles are in form of Mini-Reports.

Covers Management profile, Key Investors, Key Technology Partners, pipeline description etc.

Company Details Key Management Profile.

Key Technology Platform. Key Technology Partners, Key Investors & other Company and Cancer Drug Highlights.

Preclinical Pipeline Details with Targets and Indications Detail.

Few Sample Pages of Section F

For more details, kindly refer Table of Contents.

Highly Innovative Report contains all aspects of Oncology Drug Intelligence. First Infographics Report Figures can also be used in Presentations.
Largest Coverage First Report which covers 620+ companies with 1600+ molecules details and complete pipeline analysis. First Scientific Report which extensively focuses on technologies and drug targets. Precise Information All Efforts are done to reproduce Accurate Information.

Value for Money - The report is an excellent value for money, without

2799/- USD
Prior 28th Feb 2013 e-copy only. Including all taxes.

compromising the quality. This is all possible by reducing our marketing expenses (comprises nearly 60-70% of report cost) and utilizing more resources in developing quality content.

Price reflects approx. 4$ for Individual Company Report !!!!!!

Opinion on Oncology Intelligence 2013: During Jan 2013, about 316 free preview copies of Oncology Intelligence 2013 were distributed to Industry leaders working in area of oncology drug development through LinkedIn invitation call and nearly all of them replied very positive on the report.

We are sharing few industry leaders comment on their consent. It is an excellent report that has a wide variety of oncology information all in one place.
Dr. Oleh Denysyk

This report contains enough data to make strategic decisions especially for new entrants.
Dr. Mitsuyoshi Nishizaki

It is difficult to believe this quality of work from start up company.

Dr. Gilbert Parker

Classic work esp. Section B with facts on oncology targets and drug alliances.
Dr. Shohko Iwami

Intelligent BioSolutions

OmicsX design and develop highly innovative comprehensive intelligence reports to provide complete 3600 view to its readers. Starting 2013, every second month we are lined up with knowledge centered reports in life science. Each report reflects Team OmicsX in-depth knowledge and innovative out of the box thinking. We works for several month to craft a single original content interactive report at very competitive price, with only one aim in mind to provide quality and precise information to our clients which will help in decision support. Reports contains Insights and analysis at the company, country and disease level, which includes individual companys profiles and market data, valuations, clinical & market trends, product pipelines and forecasts. For Details and Enquiries on our Customized Services, Contact

Virendra Singhvi
Manager Business Development virendra.singhvi@omicsx.com +1-646-523-4433 +44-203-608-3536 +91-562-2281122